WE HAVE BEEN PROVEN RIGHT ON AMPYRA FROM ACORDA THERAPEUTICS
Today Acorda Therapeutics (ACOR) reported earnings. Acorda stock has risen on hopes for blockbuster sales of its MS walking drug Ampyra. First the stock went higher,
Unrivaled Performance In Bull And Bear Markets. FREE TRIALS.
|
Proven Track Record of Most Accurate Analysis
Proven Track Record
of Most Accurate Analysis
The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.
The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.
Today Acorda Therapeutics (ACOR) reported earnings. Acorda stock has risen on hopes for blockbuster sales of its MS walking drug Ampyra. First the stock went higher,
In anticipation of tomorrow’s launch of a Rare Earth ETF by Van Eck under the ticker symbol “REMX” Molycorp and Rare Earth Elements have strongly moved
www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD
Image via Wikipedia One simply needs to look at the float and the volume traded today to understand that the move up in $MCP and
www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD
On Apple’s conference call Steve Job stated that over 80% of Fortune 500 companies are running pilots for ultimate enterprise wide deployment of iPhone. This
Our model is warning of a shallow correction. The accounts giving priority to low turnover may choose to do nothing, but aggressive accounts may consider